#1. Eger, et al. J Allergy Clin Immunol Pract. 2021 Mar; 9(3):1194-1200.
#2. Domingo-Ribas, et al. Mepolizumab treatment leads to clinical remission in patients with severe eosinophilic asthma: results from the Real World REDES Study. Poster QR-32 on ATS Congress 2022.
#3. Domingo-Ribas C, et al. Real world Effectiveness and safety of mepolizubab in a multicentric Spanish cohort os asthma patients stratified by eosinophils: The REDES Study. Drugs. 2018;81(15):1763-1774.
#4. Anselmo-Lima WT, et al. Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil Braz J Otorhinolaryngol. 2021 Apr 3:S1808-8694(21)00062-8.
#5. Tomassen P, et al. Inflammatory endotypes of chronic rhinossinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449-1456.e4.
#6. Fokkens WJ, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology Journal. 2020 Feb 1;0(0):1-464.
#7. Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomized, double-blind, placebo controlled, phase 3 trial, The Lancet Respiratory Medicine; 2021; 9; 1141-1153.1.